Uro-genitaal
Metastatic prostate
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel‑Containing Regimen.
Metastatic Castration Resistant Prostate Cancer
Belgian prospective product registry to assess the use of cabazitaxel (Jevtana®) in Combination with oral Prednisone (or prednisolone) in real-life for the treatment of metastatic Castration Resistant Prostate Cancer patients
